Prestige Consumer Healthcare Inc.
PBHHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 30, 2026
Scan Results
Daily timeframePart of the healthcare sector, Prestige Consumer Healthcare Inc. (PBH) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $2.25B market cap, placing it firmly in the mid-cap category. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Market Cap
$2.25B
Beta
0.40
P/E (TTM)
12.16
P/E (Fwd)
9.37
EPS (TTM)
$3.91
EPS (Fwd)
$5.07
ROE
10.2%
ROA
5.6%
Cash
$63.9M
Total Debt
$1.05B
Free CF
$192.8M
52W Change
-44.4%
Annual Financials
Cash vs Debt
On the balance sheet, PBH has $63.9M in cash with $1.05B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $192.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 10.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $1.13B (2023) to $1.09B (2026).
With a beta below 0.7, Prestige Consumer Healthcare Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Prestige Consumer Healthcare Inc. and its sector.